AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16398603 — intervention group
Group type: COMPARATOR
Intervention: No massage (control condition)
Number of subjects: 10
Study 12404666 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 0
Study 12404666 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 0
Study 10367991 — intervention group
Group type: EXPERIMENTAL
Intervention: I2‐imidazoline receptor density in ATD patients (8.4 and 14.3 fmol/mg protein)
Number of subjects: 20
Study 10367991 — intervention group
Group type: EXPERIMENTAL
Intervention: MAO‐B activity in ATD patients
Number of subjects: 20
Study 10367991 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between I2‐imidazoline receptors and MAO‐B activity
Number of subjects: 20
Study 10367991 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive evaluation by Mini‐Mental State Examination
Number of subjects: 20
Study 7884434 — intervention group
Group type: EXPERIMENTAL
Intervention: Amonafide (300 mg/m2 daily for 5 days)
Number of subjects: 73
Study 1696799 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudoid cream
Number of subjects: 68
Study 1696799 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam gel
Number of subjects: 68
Study 1696799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 7458751 — intervention group
Group type: EXPERIMENTAL
Intervention: Various chemical agents administered to influence microcirculation and metabolism of the inner ear.
Number of subjects: 209
Study 7458751 — intervention group
Group type: COMPARATOR
Intervention: NaCl infusions and glucose tablets (control group).
Number of subjects: 209
Study 7458751 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypragmatic therapy (four different forms).
Number of subjects: 209
Study 31642928 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy for 16 weeks
Number of subjects: 152
Study 31642928 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face cognitive behavior therapy for 16 weeks
Number of subjects: 152
Study 29470571 — intervention group
Group type: EXPERIMENTAL
Intervention: MOG‐IgG positive patients (3 patients, 1.7%)
Number of subjects: 177
Study 29470571 — intervention group
Group type: EXPERIMENTAL
Intervention: AQP4‐IgG
Number of subjects: 177
Study 26830029 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced psychological care (nurse‐led mental health care coordination and behavioural activation)
Number of subjects: 64
Study 26830029 — intervention group
Group type: COMPARATOR
Intervention: Routine cardiac rehabilitation programmes alone (Control)
Number of subjects: 64
Study 24440324 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) in high-income countries
Number of subjects: 392
Study 24440324 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention in ST elevation myocardial infarction (STEMI) patients from high-income countries
Number of subjects: 392
Study 24440324 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medications at discharge in high-income countries
Number of subjects: 392
Study 22523593 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,2-octanediol lotion (20% alcohol) applied for 2-2.5 hours
Number of subjects: 641
Study 22523593 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,2-octanediol lotion (20% alcohol) applied for 8 hours/overnight
Number of subjects: 641
Study 22523593 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,2-octanediol alcohol free mousse applied for 8 hours/overnight
Number of subjects: 641
Study 22523593 — intervention group
Group type: COMPARATOR
Intervention: 0.5% malathion
Number of subjects: 641
Study 20673378 — intervention group
Group type: COMPARATOR
Intervention: Control diet + placebo capsules
Number of subjects: 57
Study 20673378 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mmol K(+)/d from fruit and vegetables
Number of subjects: 57
Study 20673378 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mmol K(+)/d from fruit and vegetables
Number of subjects: 57
Study 20673378 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mmol potassium citrate capsules/d
Number of subjects: 57
Study 20673378 — intervention group
Group type: EXPERIMENTAL
Intervention: All diets (including control)
Number of subjects: 57
Study 18159577 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine administration
Number of subjects: 0
Study 18159577 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine administration
Number of subjects: 0
Study 16115933 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxil (40 mg/m2 i.v. on day 1) and continuous infusion topotecan (0.4 mg/m2/day for 14 days)
Number of subjects: 57
Study 16115933 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral topotecan (0.4 mg/m2 bid for 14 days)
Number of subjects: 57
Study 16115933 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxil with 14‐day topotecan infusion
Number of subjects: 57
Study 16115933 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxil and continuous infusion topotecan
Number of subjects: 57
Study 16115933 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical benefit (objective responses and stable diseases)
Number of subjects: 57
Study 12392587 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin
Number of subjects: 30
Study 12392587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10200009 — intervention group
Group type: EXPERIMENTAL
Intervention: Active immunotherapy (cat/dust mite)
Number of subjects: 29
Study 10200009 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo-pollen)
Number of subjects: 29
Study 10200009 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (active immunotherapy and placebo)
Number of subjects: 29
Study 8541370 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy (CS)
Number of subjects: 67
Study 8541370 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple contrast barium enema (SCBE)
Number of subjects: 67
Study 8541370 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium enema + rectosigmoidoscopy (BERS)
Number of subjects: 67
Study 8541370 — intervention group
Group type: COMPARATOR
Intervention: Barium enema (general)
Number of subjects: 67
Study 2108586 — intervention group
Group type: EXPERIMENTAL
Intervention: Enclosed Magill breathing system
Number of subjects: 0
Study 2108586 — intervention group
Group type: COMPARATOR
Intervention: Bain breathing system
Number of subjects: 0
Study 2108586 — intervention group
Group type: COMPARATOR
Intervention: Humphrey ADE breathing system
Number of subjects: 0
Study 6796106 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral cyclophosphamide (arm S)
Number of subjects: 264
Study 6796106 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral cyclophosphamide, hexamethylmelamine and methotrexate on a pulsed basis (arm T)
Number of subjects: 264
Study 6796106 — intervention group
Group type: COMPARATOR
Intervention: Both arms (S and T)
Number of subjects: 264
Study 31467422 — intervention group
Group type: EXPERIMENTAL
Intervention: VIG
Number of subjects: 88
Study 31467422 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD
Number of subjects: 88
Study 31467422 — intervention group
Group type: EXPERIMENTAL
Intervention: BIKE
Number of subjects: 88
Study 31467422 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 88
Study 29544651 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadership team (administrator/educator) year-long interventions
Number of subjects: 8150
Study 29544651 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 8150
Study 27124881 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab monotherapy
Number of subjects: 50
Study 27124881 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone delayed delivery system monotherapy
Number of subjects: 50
Study 24535625 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin (1-25 mg single dose)
Number of subjects: 0
Study 24535625 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin (5 or 10 mg/day for 7 days)
Number of subjects: 0
Study 24535625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22429452 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological gamblers
Number of subjects: 40
Study 22429452 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 20862940 — intervention group
Group type: EXPERIMENTAL
Intervention: Shallow needling combined with acupoint application on top of routine medication.
Number of subjects: 120
Study 20862940 — intervention group
Group type: COMPARATOR
Intervention: Routine medication (control group).
Number of subjects: 120
Study 19049703 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,200 mg twice daily + bicarbonate hydration
Number of subjects: 60
Study 15709658 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought Translation Device (TTD) with integrated Detection of Cognitive Activity (DCA)
Number of subjects: 10
Study 15709658 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 10
Study 14734261 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week behavior modification program
Number of subjects: 184
Study 14734261 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 184
Study 10889804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diet-exercise programme
Number of subjects: 523
Study 10889804 — intervention group
Group type: COMPARATOR
Intervention: General information about weight reduction, physical activity and healthy diet
Number of subjects: 523
Study 9364366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent testosterone enanthate treatment (25‐100 mg every two weeks for three months)
Number of subjects: 22
Study 1467514 — intervention group
Group type: EXPERIMENTAL
Intervention: BCR-ABL positive group
Number of subjects: 56
Study 1467514 — intervention group
Group type: COMPARATOR
Intervention: BCR-ABL negative group
Number of subjects: 56
Study 3971528 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental low-energy protocol from 0.03 to 2.2 J (group A, 11 patients)
Number of subjects: 22
Study 3971528 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental high-energy protocol from 0.5 to 10.0 J (group B, 11 patients)
Number of subjects: 22
Study 3971528 — intervention group
Group type: COMPARATOR
Intervention: Control (drug-free state)
Number of subjects: 22
Study 3971528 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug therapy
Number of subjects: 22
Study 3971528 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall efficacy of transvenous cardioversion
Number of subjects: 22
Study 3971528 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful transvenous cardioversion
Number of subjects: 22
Study 3971528 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient arrhythmias after cardioversion
Number of subjects: 22
Study 3971528 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceleration of VT
Number of subjects: 22
Study 3971528 — intervention group
Group type: EXPERIMENTAL
Intervention: Termination of shock protocols due to acceleration of VT
Number of subjects: 22
Study 3971528 — intervention group
Group type: EXPERIMENTAL
Intervention: Displacement of electrode catheters after transvenous cardioversion
Number of subjects: 22
Study 31121375 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic gelatin sponge impregnated with ropivacaine 0.5%
Number of subjects: 30
Study 31121375 — intervention group
Group type: COMPARATOR
Intervention: Normal saline NaCl 0.9%
Number of subjects: 30
Study 29516990 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 150 mg/day and cinobufagin 2700 mg/day
Number of subjects: 54
Study 29516990 — intervention group
Group type: COMPARATOR
Intervention: Cinobufagin 2700 mg/day (Control)
Number of subjects: 54
Study 26849844 — intervention group
Group type: EXPERIMENTAL
Intervention: SEP-432 (300 mg/day)
Number of subjects: 18
Study 26849844 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg/day)
Number of subjects: 18
Study 26849844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 25391194 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg folic acid for 2 months
Number of subjects: 50
Study 25391194 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 50
Study 22227760 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-run course 'Recovery Is Up to You' for 12 weeks
Number of subjects: 333
Study 22227760 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 333
Study 20131040 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture in the non-anesthesia area (NAA) group
Number of subjects: 60
Study 20131040 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 60
Study 20131040 — intervention group
Group type: COMPARATOR
Intervention: Anesthesia area (AA) group
Number of subjects: 60
Study 18455727 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pill phase (oral contraceptives)
Number of subjects: 36
Study 18455727 — intervention group
Group type: COMPARATOR
Intervention: Early follicular phase (naturally cycling women)
Number of subjects: 36
Study 18455727 — intervention group
Group type: COMPARATOR
Intervention: Midluteal phase (naturally cycling women)
Number of subjects: 36
Study 15932917 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin therapy
Number of subjects: 28
Study 15932917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 15932917 — intervention group
Group type: COMPARATOR
Intervention: PCOS patients without metformin therapy
Number of subjects: 28
Study 12940609 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (20 mg) and dipyridamole (5 mg/kg) for 1 year
Number of subjects: 30
Study 12940609 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole (5 mg/kg) only for 1 year
Number of subjects: 30
Study 10395628 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-culture yogurt (200 g/d for 1 year)
Number of subjects: 0
Study 10395628 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteurized yogurt (200 g/d for 1 year)
Number of subjects: 0
Study 10395628 — intervention group
Group type: COMPARATOR
Intervention: Control (no yogurt)
Number of subjects: 0
Study 8734343 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 90
Study 8734343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 1763597 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin injection
Number of subjects: 10
Study 1763597 — intervention group
Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 10
Study 6507426 — intervention group
Group type: EXPERIMENTAL
Intervention: Rising socioeconomic status in Mexican American women
Number of subjects: 2217
Study 6507426 — intervention group
Group type: EXPERIMENTAL
Intervention: Rising socioeconomic status in Mexican American men
Number of subjects: 2217
Study 6507426 — intervention group
Group type: COMPARATOR
Intervention: Comparison of diabetes prevalence
Number of subjects: 2217
Study 6507426 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 'obesity-related' risk factors
Number of subjects: 2217
Study 31556652 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided online F-PST (n = 56)
Number of subjects: 150
Study 31556652 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided online F-PST (n = 60)
Number of subjects: 150
Study 31556652 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face F-PST (n = 34)
Number of subjects: 150
Study 31556652 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-proxy HBI ratings
Number of subjects: 150
Study 30169462 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygiene information and advice
Number of subjects: 0
Study 30169462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins
Number of subjects: 0
Study 30169462 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 8 g daily
Number of subjects: 0
Study 27249781 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg LSD
Number of subjects: 40
Study 27249781 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg LSD
Number of subjects: 40
Study 27249781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24286542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear acupressure on four designated acupressure points on both ears
Number of subjects: 256
Study 24286542 — intervention group
Group type: COMPARATOR
Intervention: Tapes on four irrelevant points (Control)
Number of subjects: 256
Study 22326464 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of methylprednisolone
Number of subjects: 90
Study 22326464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 20857371 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated NG‐Shield device
Number of subjects: 24
Study 20857371 — intervention group
Group type: COMPARATOR
Intervention: Nonactive NG‐Shield device
Number of subjects: 24
Study 23057605 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive underfeeding (50% of calculated caloric requirement)
Number of subjects: 862
Study 23057605 — intervention group
Group type: COMPARATOR
Intervention: Target feeding (100% of calculated caloric requirement)
Number of subjects: 862
Study 23057605 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive underfeeding
Number of subjects: 862
Study 23057605 — intervention group
Group type: COMPARATOR
Intervention: Target feeding
Number of subjects: 862
Study 15936423 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (methylprednisolone) administered via a 48-hour infusion
Number of subjects: 10008
Study 15936423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10008
Study 12007755 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO‐SELF Copyright Pain Control Program
Number of subjects: 85
Study 12007755 — intervention group
Group type: COMPARATOR
Intervention: Provision of information about cancer pain management
Number of subjects: 85
Study 10473926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (single dose)
Number of subjects: 195
Study 10473926 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (3 times a day for 3 days)
Number of subjects: 195
Study 10473926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 195
Study 10473926 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 195
Study 8712912 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral laparoscopic adrenalectomy
Number of subjects: 36
Study 8712912 — intervention group
Group type: COMPARATOR
Intervention: Posterior laparoscopic adrenalectomy
Number of subjects: 36
Study 8712912 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 36
Study 1718250 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment (argon green or krypton red lasers)
Number of subjects: 362
Study 1718250 — intervention group
Group type: COMPARATOR
Intervention: Untreated eyes
Number of subjects: 362
Study 7074317 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic heparinization
Number of subjects: 50
Study 7074317 — intervention group
Group type: COMPARATOR
Intervention: Control (non-heparinized patients)
Number of subjects: 50
Study 29953509 — intervention group
Group type: EXPERIMENTAL
Intervention: New onset atrial fibrillation (NOAF)
Number of subjects: 5130
Study 28850499 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric activation (ISOM) of deep multifidi muscles
Number of subjects: 24
Study 28850499 — intervention group
Group type: COMPARATOR
Intervention: Global activation of paravertebral muscles (GLOB)
Number of subjects: 24
Study 25913873 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated lighting systems in classrooms (intervention arm: 178 students)
Number of subjects: 317
Study 22956062 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical follow-up (experimental arm)
Number of subjects: 247
Study 22956062 — intervention group
Group type: COMPARATOR
Intervention: Complete axillary lymph node dissection (control arm)
Number of subjects: 247
Study 22956062 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (control and experimental)
Number of subjects: 247
Study 20572378 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic product of a single oral 8 mg rosiglitazone tablet
Number of subjects: 24
Study 20572378 — intervention group
Group type: COMPARATOR
Intervention: Innovator's product of a single oral 8 mg rosiglitazone tablet
Number of subjects: 24
Study 20572378 — intervention group
Group type: COMPARATOR
Intervention: Comparison of generic product to innovator's product
Number of subjects: 24
Study 17637602 — intervention group
Group type: EXPERIMENTAL
Intervention: Almonds (raw, dry unsalted roasted, natural sliced, roasted salted, honey roasted)
Number of subjects: 24
Study 17637602 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted condition
Number of subjects: 24
Study 17637602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliced almonds
Number of subjects: 24
Study 17637602 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of chews and mastication time
Number of subjects: 24
Study 17637602 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond form or flavor
Number of subjects: 24
Study 15858965 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolysed formula (formula A)
Number of subjects: 21
Study 15858965 — intervention group
Group type: COMPARATOR
Intervention: Conventional preterm infant formula (formula B)
Number of subjects: 21
Study 12682308 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (50 mg per os twice a day)
Number of subjects: 58
Study 12682308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 11110418 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes simplex virus thymidine kinase/ganciclovir (HSV‐tk/GCV) gene therapy by direct intracerebral injection of retrovirus (RV) vector producing cells (VPC) during tumor surgery and subsequent systemic administration of GCV
Number of subjects: 13
Study 11110418 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes simplex virus thymidine kinase/ganciclovir (HSV‐tk/GCV) gene therapy
Number of subjects: 13